☆ 4.5 Letter

Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series

INFLAMMATORY BOWEL DISEASES (2016)

Journal

INFLAMMATORY BOWEL DISEASES

Volume 22, Issue 10, Pages E39-E40

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1097/MIB.0000000000000906

Keywords

-

Categories

Gastroenterology & Hepatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Pre-Diagnostic Saliva Microbiota of School-Aged Children Who Developed Type 1 Diabetes or Inflammatory Bowel Diseases

Laura Raisanen, Nitin Agrawal, Binu Mathew, Sohvi Kaariainen, Kaija-Leena Kolho, Heli Viljakainen

Summary: The composition and diversity of saliva microbiota are not successful predictors for pediatric type 1 diabetes mellitus (T1D) or inflammatory bowel diseases (IBD). However, the relative abundances of certain bacteria are altered before the onset of T1D, and the metabolic pathway PWY-5677 is predicted to be lowered. Investigating functional pathways might provide a better approach in searching for biomarkers for autoimmune disease in the future.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Pharmacology & Pharmacy

Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease

Jurij Hanzel, Christopher Ma, Niels Vande Casteele, Reena Khanna, Vipul Jairath, Brian G. Feagan

Summary: In Crohn's disease and ulcerative colitis patients, extraintestinal manifestations can affect up to 50% of patients, mainly involving the musculoskeletal system and skin, with less common involvement of the hepatobiliary tract and eye. The pathophysiology of EIMs is poorly understood but may involve abnormal immune responses and cross-reactivity with self-antigens. Tumor necrosis factor antagonists have shown efficacy in treating EIMs, while vedolizumab's efficacy in treating EIMs remains uncertain.

DRUGS (2021)

Add to Collection

Article Gastroenterology & Hepatology

The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study

Guilherme Piovezani Ramos, Christina Dimopoulos, Nicholas M. McDonald, Laurens P. Janssens, Kenneth W. Hung, Deborah Proctor, Elizabeth Ruggiero, Sunanda Kane, David H. Bruining, William A. Faubion, Laura E. Raffals, Edward Loftus, Badr Al-Bawardy

Summary: The study found that approximately one-third of IBD patients experienced worsening EIMs after VDZ treatment, with peripheral arthritis being the most common type. Worsening of EIMs led to discontinuation of VDZ treatment, but there were no significant differences between the worsening and stable EIMs groups.

INFLAMMATORY BOWEL DISEASES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Fecal Microbiota Transplantation in Inflammatory Bowel Disease

Adrian Boicean, Victoria Birlutiu, Cristian Ichim, Paula Anderco, Sabrina Birsan

Summary: Inflammatory bowel diseases (IBD) are complex diseases characterized by chronic inflammation in the gastrointestinal tract. Fecal microbiota transplantation (FMT) has shown increasing effectiveness and safety in treating recurrent Clostridium difficile infection (CDI) and co-infection of SARS-CoV-2 and CDI. By modifying the gut microbiota, FMT offers an alternative approach to indirectly influence the host's immune system in a safe way, improving clinical symptoms and endoscopic findings in IBD patients. Further validation is needed to establish a clinical protocol for FMT in IBD.

BIOMEDICINES (2023)

Add to Collection

Article Nutrition & Dietetics

The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab

Bincy P. Abraham, Christopher Fan, Theresa Thurston, Joshua Moskow, Hoda M. Malaty, Lynnette Ferguson

Summary: This study assessed the impact of vitamin D levels on the efficacy of vedolizumab therapy in Inflammatory Bowel Disease (IBD) patients. The results showed that higher pre-treatment vitamin D levels predicted significant endoscopic improvement in patients with ulcerative colitis (UC), and improving vitamin D levels significantly lowered C-reactive protein levels in patients with Crohn's disease (CD).

NUTRIENTS (2023)

Add to Collection

Review Cell Biology

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases

Matthew Luzentales-Simpson, Yvonne C. F. Pang, Ada Zhang, James A. Sousa, Laura M. Sly

Summary: Inflammatory bowel diseases are characterized by chronic inflammation along the gastrointestinal tract due to excessive leukocyte infiltration. Current treatments include aminosalicylates, corticosteroids, immunosuppressants, and biologics such as anti-TNF antibodies, although some patients may become unresponsive to anti-TNF therapy.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]

Esther Ventress, David Young, Sohail Rahmany, Clare Harris, Marion Bettey, Trevor Smith, Helen Moyses, Magdalena Lech, Markus Gwiggner, Richard Felwick, J. R. Fraser Cummings

Summary: This study evaluated the clinical and biochemical outcomes of transitioning IBD patients established on IV vedolizumab to SC treatment, and found that the transition was safe and effective with high patient satisfaction.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Article Medicine, General & Internal

Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease

Ruben Y. Gabriels, Arno R. Bourgonje, Julius Z. H. von Martels, Tjasso Blokzijl, Rinse K. Weersma, Kevin Galinsky, Julius Juarez, Klaas Nico Faber, Gursah Kats-Ugurlu, Gerard Dijkstra

Summary: This study aimed to explore the predictive value of mucosal eosinophils and serum eotaxin-1 regarding response to vedolizumab induction therapy in patients with inflammatory bowel disease (IBD). The results showed that mucosal eosinophil abundance in non-inflamed colonic tissue and baseline serum eotaxin-1 levels were associated with response to vedolizumab treatment. However, the predictive capacity of baseline serum eotaxin-1 levels could not be validated in another study cohort.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Medicine, General & Internal

Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders

Cristiana Bianco, Elena Coluccio, Daniele Prati, Luca Valenti

Summary: Anemia is a common feature of liver and bowel diseases, and autoimmune hemolytic anemia should be considered in differential diagnosis. Prompt treatment based on direct antiglobulin test results is crucial, while drug-induced immune-mediated hemolytic anemia should be ruled out. Maintaining a high clinical suspicion for timely diagnosis and appropriate treatment is essential due to the adverse impact of anemia on clinical outcomes.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Preoperative Serum Vedolizumab Levels Do Not Impact Postoperative Outcomes in Inflammatory Bowel Disease

Aaron B. Parrish, Nicole E. Lopez, Adam Truong, Karen Zaghiyan, Gil Y. Melmed, Dermot P. B. McGovern, Christina Ha, Gaurav Syal, Nirupama Bonthala, Anjali Jain, Carol J. Landers, Stephan R. Targan, Phillip Fleshner

Summary: This study found that serum vedolizumab levels do not affect postoperative morbidity in patients with IBD, but may help reduce the incidence of postoperative ileus in patients with Crohn's disease.

DISEASES OF THE COLON & RECTUM (2021)

Add to Collection

Article Pharmacology & Pharmacy

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment-TUMMY Study

Merve Sivridas, Rob H. Creemers, Dennis R. Wong, Paul J. Boekema, Tessa E. H. Romkens, Lennard P. L. Gilissen, Adriaan A. van Bodegraven, Floris C. Loeff, Theo Rispens, Luc J. J. Derijks

Summary: The aim of this study was to determine the association between vedolizumab (VDZ) trough concentration and clinical and biochemical remission in the maintenance phase. The results showed no statistically significant correlation between VDZ concentration and clinical remission in all patient groups. However, patients in biochemical remission had higher VDZ trough concentrations. Therefore, there is an association between VDZ concentration and biochemical remission, but not with clinical remission.

PHARMACEUTICS (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Inflammatory Bowel Diseases and Gut Microbiota

Yuri Haneishi, Yuma Furuya, Mayu Hasegawa, Antonio Picarelli, Mauro Rossi, Junki Miyamoto

Summary: Inflammatory bowel disease (IBD) is a rapidly increasing inflammatory disease of the gastrointestinal tract worldwide. Recent research suggests that factors such as genetics, environment, microbiota, and immune responses are involved in its development, but the underlying causes are unclear. Dysbiosis of gut microbiota, particularly a decrease in specific genera, has been identified as a possible trigger for IBD. Improving gut microbiota and identifying specific bacterial species are crucial for understanding and treating IBD and autoimmune diseases.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Gastroenterology & Hepatology

Alterations in the Course of Inflammatory Bowel Disease Following Liver Transplantation: A Systematic Review and Meta-analysis

Ali Reza Safarpour, Sara Shojaei-Zarghani, Manoosh Mehrabi, Abbas Ali Keshtkar, Ali Akbar Oroojan, Gholam Reza Sivandzadeh

Summary: Our meta-analysis found that the majority of inflammatory bowel disease (IBD) patients undergoing liver transplantation experience no change (or improvement/no change) in IBD activity. The type of IBD, age, and follow-up length may influence the course of IBD after liver transplantation.

INFLAMMATORY BOWEL DISEASES (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases

Yuan Shi, Wei He, Ming Zhong, Minhao Yu

Summary: IFX/ADA and VDZ are widely used biologics for inflammatory bowel diseases, and the GIMATS module showed the best performance in predicting patient responses, dividing them into metabolic, immune, and normal types. A simplified 6-gene model called MIN score was established as a substitute for GIMATS module to assist with IFX/ADA and VDZ selection based on patient classification.

GENOMICS (2021)

Add to Collection

Review Immunology

IgG subclass and Fc glycosylation shifts are linked to the transition from pre- to inflammatory autoimmune conditions

Jana Sophia Buhre, Mareike Becker, Marc Ehlers

Summary: The development of inflammatory autoimmune diseases involves two steps, from harmless self-directed antibody responses to more inflammatory responses. Identifying biomarkers that signal the transition from the pre-disease to the disease stage can help determine the optimal time to initiate treatment and develop therapeutic strategies.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, Millie Long, Matthieu Allez, Pascal Juillerat, Alessandro Armuzzi, Edward Loftus, Elham Ostad-Saffari, Astrid Scalori, Young S. Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Stuart Lacey, William J. Sandborn

Summary: This study evaluated the efficacy and safety of etrolizumab in patients with moderately to severely active ulcerative colitis who had been previously treated with anti-TNF agents. The results showed that etrolizumab significantly improved remission rates at week 14 compared to placebo, but there was no significant difference between the two groups in remission rates at week 66.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

Silvio Danese, Severine Vermeire, Geert D'Haens, Julian Panes, Axel Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravata, Frederic Lavie, Marco Daperno, Milan Lukas, Alessandro Armuzzi, Mark Lowenberg, Daniel R. Gaya, Laurent Peyrin-Biroulet

Summary: In patients with moderate-to-severe active Crohn's disease, a treat-to-target strategy with early endoscopy, biomarker monitoring, and dose intensification did not result in significantly better endoscopic outcomes at week 48 compared to a clinically driven maintenance strategy.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD Centre

Susanna Meade, Kamal V. Patel, Raphael P. Luber, Dearbhaile O'Hanlon, Andra Caracostea, Polychronis Pavlidis, Sailish Honap, Cheran Anandarajah, Nyree Gryffin, Sebastian Zeki, Shuvra Ray, Joel Mawdsley, Mark A. Samaan, Simon H. Anderson, Amir Darakhshan, Katie Adams, Andrew Williams, Jeremy D. Sanderson, Miranda Lomer, Peter M. Irving

Summary: This study found that pre-operative oral enteral nutrition in patients with Crohn's disease undergoing surgery was associated with reduced postoperative complications, particularly non-surgical complications and infectious complications.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Review Allergy

Regulatory T cells and immunoglobulin E: A new therapeutic link for autoimmunity?

Oscar Palomares, Dirk Elewaut, Peter M. Irving, Xavier Jaumont, Paolo Tassinari

Summary: Autoimmune diseases have a high prevalence rate, but effective and targeted treatments are still lacking. Regulatory T cells play an important role in many autoimmune diseases, and immunoglobulin E also appears to be involved in autoimmune diseases. Anti-IgE treatment may restore the balance of regulatory T cells and could be used in the treatment of autoimmune diseases involving regulatory T cells.

ALLERGY (2022)

Add to Collection

Letter Gastroenterology & Hepatology

Ustekinumab-Induced Inflammatory Demyelinating Polyneuropathy in a Patient with Ulcerative Colitis

Sailish Honap, Peter M. Irving, Mark A. Samaan

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Positioning intestinal ultrasound in a UK tertiary centre: significant estimated clinical role and cost savings

Raphael P. Luber, Bianca Petri, Susanna Meade, Sailish Honap, Sebastian Zeki, Krisztina B. Gecse, Nyree Griffin, Peter M. Irving

Summary: The study showed that intestinal ultrasound (IUS) can be an effective alternative to lower gastrointestinal endoscopies (LGIEs) and magnetic resonance enterographies (MREs), with potential cost savings. There were no significant pathologies missed with IUS, and the limited pathology found in patients not suitable for IUS had limited clinical significance.

FRONTLINE GASTROENTEROLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn's and Colitis Organisation [ECCO] Position Paper

Jurij Hanzel, Peter Bossuyt, Valerie Pittet, Mark Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Johan Burisch, Salvatore Leone, Roberto Saldana, Filip Baert, Uri Kopylov, Susanna Jaghult, Michel Adamina, Naila Arebi, Krisztina Gecse

Summary: This study aimed to develop a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Candidate outcomes and outcome measures were identified through a systematic review and a modified Delphi consensus process. The international panel agreed on the final core outcome set, which will facilitate the synthesis and generation of real-world evidence.

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Article Oncology

Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis

James L. Alexander, Hajir Ibraheim, Camellia Richards, Ben Shum, Polychronis Pavlidis, Nikki Hunter, Julian P. Teare, Andrew Wotherspoon, Andrew Furness, Samra Turajlic, Lisa Pickering, James Larkin, Ally Speight, Sophie Papa, Nick Powell

Summary: This study aimed to evaluate the efficacy of the topically acting oral corticosteroid beclomethasone dipropionate (BD) in treating CPI-induced colitis. The results of the study showed that BD treatment was effective and safe in treating this condition. In patients with CPI-induced colitis, BD induced remission and restored baseline stool frequency.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Gastroenterology & Hepatology

How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes?

Susanna Meade, Emma Routledge, Esha Sharma, Sailish Honap, Sebastian Zeki, Shuvra Ray, Simon H. C. Anderson, Jeremy Sanderson, Joel Mawdsley, Peter M. Irving, Mark A. Samaan

Summary: The study evaluated the feasibility of using SES-CD as a treatment target for Crohn's disease, and found that achieving the set endpoints was associated with reduced rates of treatment failure.

FRONTLINE GASTROENTEROLOGY (2023)

Add to Collection

Letter Gastroenterology & Hepatology

Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research

James L. Alexander, Nicola J. Wyatt, Stephane Camuzeaux, Elena Chekmeneva, Beatriz Jimenez, Caroline J. Sands, Hannah Fuller, Panteleimon Takis, Tariq Ahmad, Jennifer A. Doyle, Ailsa Hart, Peter M. Irving, Nicholas A. Kennedy, Charlie W. Lees, James O. Lindsay, Rebecca E. McIntyre, Miles Parkes, Natalie J. Prescott, Tim Raine, Jack Satsangi, Richard Alexander Speight, Luke Jostins-Dean, Nick Powell, Julian R. Marchesi, Christopher J. Stewart, Christopher A. Lamb

GUT (2023)

Add to Collection

Article Gastroenterology & Hepatology

JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice

Sailish Honap, Peter M. Irving, Mark A. Samaan

Summary: This study reveals that despite clinical practices appearing to align with international guidelines, a significant minority of healthcare providers remain deterred by safety concerns.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Extracellular vesicles in COVID-19 convalescence can regulate T cell metabolism and function

Molly S. George, Jenifer Sanchez, Christina Rollings, David Fear, Peter Irving, Linda V. Sinclair, Anna Schurich

Summary: Long-term T cell dysregulation following COVID-19 disease is associated with disease severity and long-covid symptoms. Alterations in cellular origin and protein content of extracellular vesicles (EV) during COVID-19 convalescence are linked to initial disease severity. EV derived from convalescent donors can affect the function and metabolic rewiring of CD4 and CD8 T cells, with immune-suppressive properties observed in mild cases.

ISCIENCE (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

LONGER-TERM TOFACITINIB EFFECTIVENESS FOR THE TREATMENT OF ULCERATIVE COLITIS: TWO-YEAR OUTCOMES FROM A UK OBSERVATIONAL COHORT STUDY

Sailish Honap, Esha Sharma, Shuyra Ray, Joel Mawdsley, Simon H. Anderson, Mark A. Samaan, Polychronis Pavlidis, Peter M. Irving

GASTROENTEROLOGY (2022)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Pre-operative oral enteral nutritional optimisation for Crohn's disease: A retrospective UK tertiary IBD centre cohort study

S. Meade, K. V. Patel, R. P. Luber, D. O'Hanlon, A. Caracostea, P. Pavlidis, S. Honap, C. Anandarajah, N. Griffin, S. Zeki, S. Ray, J. Mawdsley, M. A. Samaan, S. H. Anderson, A. Darakhshan, K. Adams, A. Williams, J. D. Sanderson, M. Lomer, P. M. Irving

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.